Researchers at Flinders University and South China University of Technology identified two crucial enzymes that could lead to targeted treatments for Prostate cancer by exploiting the Androgen receptors vulnerabilities.
- International research led by Flinders University in Australia discovered that the enzymes PDIA1 and PDIA5 are critical for Prostate cancer cell growth and treatment resistance.
- The Androgen receptor protein, which fuels Prostate cancer, is protected by these enzymes, acting as molecular bodyguards that enhance cancer cell survival.
- Findings may pave the way for improved treatments for Prostate cancer, potentially offering new strategies to combat resistance to existing therapies like Enzalutamide.
Why It Matters
This breakthrough in understanding the role of enzymes in Prostate cancer could revolutionize treatment approaches, affecting millions of patients and aligning with ongoing efforts to enhance cancer therapies globally.